# Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

> **NCT04635956** · PHASE2 · UNKNOWN · sponsor: **Lei Li** · enrollment: 20 (estimated)

## Conditions studied

- Chemotherapy
- Anti-pd-1 Antibody
- Cervical Neuroendocrine Carcinoma
- Adverse Drug Event
- Recurrent Cervical Carcinoma
- Advanced Cervical Carcinoma
- Objective Response Rate

## Interventions

- **DRUG:** Drug therapy

## Key facts

- **NCT ID:** NCT04635956
- **Lead sponsor:** Lei Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-15
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635956, "Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04635956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*